Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AAPB in Healthy Chinese Subjects
NCT06679998Phase 1Not yet recruiting
- Sponsor
- Jiangsu Kanion Pharmaceutical Co., Ltd.
- Start
- Nov 2024
- Primary completion
- Jan 2026
- Modality
- Reversible Covalent Inhibitors, Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of 2-aminoethoxydiphenylborate in ischemic stroke (14 arms), sponsored by Jiangsu Kanion Pharmaceutical Co., Ltd. Primary endpoint: Adverse event. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
2-aminoethoxydiphenylborate
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06679998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06679998.